Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P39060 (endostatin)
 2,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Experiments were designed to study the importance of organic acids as counterions for K(+) translocation in the xylem during excess cation uptake. A comparison was made of xylem exudate from wheat seedlings treated 72 hours with either 1.0 millimolar KNO(3) or 0.5 millimolar K(2)SO(4), both in the presence of 0.2 millimolar CaSO(4). Exudation from KNO(3) plants had twice the volume and twice the K(+) and Ca(2+) fluxes or rate of delivery to shoots, as K(2)SO(4) plants. Malate flux was 25% higher in K(2)SO(4) than in KNO(3) exudate. Malate was the principal anion accompanying K(+) or Ca(2+) in K(2)SO(4) treatment, while in the KNO(3) treatment, NO(3) (-) was the principal anion. The contribution of SO(4) (2-) was negligible in both treatments. In a second experiment, exudate was collected every 4 hours during the daytime throughout a 72-hour treatment with KNO(3). Malate was the only anion present in exudate at first, just after the CaSO(4) pretreatment had ended. Malate concentration decreased and NO(3) (-) concentration increased with time and these concentrations were negatively correlated. By 62 hours, NO(3) (-) represented 80% of exudate anions. K(+) and NO(3) (-) concentrations in exudate were strongly correlated with K(+) and NO(3) (-) uptake, respectively. The first 36 hours of absorption from KNO(3) solution resembled the continuous absorption of K(2)SO(4), in that malate was the principal counterion for translocation of K(+).
 ...
PMID:Organic Acids and Ionic Balance in Xylem Exudate of Wheat during Nitrate or Sulfate Absorption. 1666 Dec 48

The aim of the study was to evaluate the activity of the antiangiogenic agent SU-11248 (sunitinib malate, Sutent), alone or in combination with docetaxel. To this end, animals bearing DU-145 human hormone-refractory prostate cancer (HRPC) xenografts were treated with sunitinib (40 mg/kg daily, p.o.), docetaxel (10 or 30 mg/kg/week, i.v.), a combination of sunitinib (40 mg/kg daily) and docetaxel (10 mg/kg/week) or vehicle alone. At the end of the 3-week dosing schedule, single-agent treatment induced a tumor regression of 59%, 49% and 75% for sunitinib, docetaxel 10mg/kg, and docetaxel 30 mg/kg, respectively. The combination of sunitinib with low-dose (10mg/kg) docetaxel produced a tumor regression comparable to that obtained with high-dose (30 mg/kg) docetaxel, but tolerability was higher as indicated by mice weight. Both sunitinib and docetaxel inhibited tumor regrowth after initial treatment with the alternate drug. These results suggest that sunitinib alone or in combination with low-dose docetaxel may have a role in the treatment of HRPC.
 ...
PMID:Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 1858 84